STING activation reduces graft-versus-host disease in a mouse model
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
12 February 2021Covid-19: Is Manaus the final nail in the coffin for natural herd immunity?
12 February 2021STING activation reduces graft-versus-host disease in a mouse model
MUSC Hollings Cancer Center researcher Yongxia Wu, Ph.D., identified a new target molecule in the fight against graft-versus-host disease (GVHD). Bone marrow transplant, a treatment for certain blood cancers, is accompanied by potentially life-threatening GVHD in nearly 50% of patients. A January 2021 paper published in Cellular and Molecular Immunology revealed that activating a molecule called STING may be a new approach to reduce GVHD.
